Hyaluronic acid

Generic Name: Hyaluronic acid

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₄₄N_₂O_₂₃

CAS Number: 9004-61-9

Unique Ingredient Identifier: S270N0TRQY

Background: Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan found in connective, epithelial, and neural tissues; it was first isolated in 1934. Karl Meyer and John Palmer obtained glycosaminoglycan (GAG) from the bovine eye, giving it the name “hyaluronic acid”. HA is involved in many important physiological processes, including but not limited to woun...

Indication: The intra-articular preparations of hyaluronic acid are indicated for knee pain associated with osteoarthritis. Hyaluronic acid is used in cosmetic applications to prevent and reduce the appearance of wrinkles on the face, and as a dermal filler to correct facial imperfections or other imperfections on other parts of the body. It is frequently an ingredient ...

Associated Conditions: Actinic Keratosis (AK), Burns, Chronic Skin Ulcers, Conjunctivitis, Dehydration, Dermabrasion, Dermatosis, Dry Eyes, Facial Defect, Interstitial Cystitis, Keratoconjunctivitis, Ocular Irritation, Osteoarthritis (OA), Pain of the knee, Seasonal Allergic Conjunctivitis, Skin Burn, Skin Irritation, Skin fissures, Tissue Adhesions, Varicose Ulcers, Wound, Eye discomfort, Facial fine wrinkling, Sensation of burning in the eyes, Superficial Wounds

Associated Therapies: Dermal Filler, Promotion of wound healing, Synovial Fluid Lubrication

Clinical Trials

Glans Penis Augmentation by Hyaluronic Acid for Treatment of Premature Ejaculation

Phase 3

Completed

Conditions: Premature Ejaculation

Interventions: Drug: Hyaluronic Acid

First Posted Date: 2018-03-09

Last Posted Date: 2018-03-13

Lead Sponsor: Cairo University

Target Recruit Count: 30

Registration Number: NCT03459833

A Validation Study of Sodium Hyaluronate in Patients With Periarthritis of Shoulder

Not Applicable

Conditions: Periarthritis

Interventions: Drug: Sodium Hyaluronate
Drug: Aerzhi

First Posted Date: 2017-12-07

Last Posted Date: 2017-12-07

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 260

Registration Number: NCT03365388

Locations: 🇨🇳
Peking University People's Hospital, Peking, Beijing, China

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

Phase 1

Completed

Conditions: Degenerative Disc Disease

Interventions: Biological: IDCT
Drug: Saline Solution
Drug: Sodium Hyaluronate

First Posted Date: 2017-11-20

Last Posted Date: 2023-01-25

Lead Sponsor: DiscGenics, Inc.

Target Recruit Count: 60

Registration Number: NCT03347708

Locations: 🇺🇸
Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸
UC San Diego CIRM Alpha Stem Cell Clinic, San Diego, California, United States
🇺🇸
Otrimed, Edgewood, Kentucky, United States

and more 11 locations

Evaluation of Methods of Teaching Self-management Strategies to Patients With Symptomatic Knee Osteoarthritis

Phase 4

Completed

Conditions: Osteoarthritis, Knee

Interventions: Other: Educational handout
Drug: Hyaluronic Acid
Other: Verbal script

First Posted Date: 2017-08-10

Last Posted Date: 2019-11-05

Lead Sponsor: Hospital for Special Surgery, New York

Target Recruit Count: 24

Registration Number: NCT03245463

Locations: 🇺🇸
Hospital for Special Surgery, New York, New York, United States

Intra-articular Adipose Tissue Injections for Osteoarthritis

Not Applicable

Conditions: Osteoarthritis, Knee

Interventions: Biological: Autologous adipose tissue injection
Drug: Hyaluronic Acid

First Posted Date: 2017-08-08

Last Posted Date: 2019-10-03

Lead Sponsor: University of Southern California

Target Recruit Count: 54

Registration Number: NCT03242707

Locations: 🇺🇸
Keck Medicine of USC, Los Angeles, California, United States

Efficacy of Hyaluronic Acid and Platelet-rich Plasma Combination in Knee Osteoarthritis

Phase 4

Completed

Conditions: Knee Osteoarthritis

Interventions: Drug: hyaluronic Acid + platelet-rich plasma
Drug: platelet-rich plasma
Drug: hyaluronic acid

First Posted Date: 2017-07-07

Last Posted Date: 2021-06-14

Lead Sponsor: University of Milan

Target Recruit Count: 174

Registration Number: NCT03211650

Locations: 🇮🇹
U.O.C. 1a Divisione, Azienda Socio Sanitaria Territoriale Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milano, Milan, Italy
🇮🇹
IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy